We, along with others, have previously identified overexpression of the metalloproteinases ADAM10 and ADAM17 in glioblastoma [5–7], where increased ADAM10 or ADAM17 expression correlates with poorer prognosis [8, 9]. Here, ADAM10 is linked to glioblastoma.